Company
We do not just support Targeted Alpha Therapy — we help make it possible.
Southern Cross Medical Radioisotopes (SCMR) is an advanced nuclear medicine company developing next-generation radioisotope production technologies to supply critical medical isotopes for cancer diagnosis and Targeted Alpha Therapy (TAT), strengthening Australia's sovereign capability in life-saving nuclear medicine.
The company is part of a wave of Australian companies in advanced and specialised healthcare sectors.
Pioneering High-Purity Actinium-225 Production
SCMR is developing advanced production and separation technologies to create a reliable, scalable supply of high-purity Ac-225 for medical use.
Our program builds on pioneering research that demonstrated how electron accelerators can produce Ac-225, opening new pathways for medical radioisotope generation.
Our work integrates:
-
Electron accelerator–based production: Utilising photonuclear reaction pathways.
-
High-efficiency separation: Modern radiochemical systems and medical-grade purification.
-
Multidisciplinary science: A combination of nuclear physics, accelerator science, and radiochemistry.
-
Medical translation: Bridging the gap between fundamental science and clinical cancer treatment.
This approach enables flexible production independent of traditional reactor supply chains.
Why this matters.
Global access to Targeted Alpha Therapy (TAT) is currently limited by isotope availability.
Every increase in our production capacity strengthens the foundation of radioisotope supply and helps unlock the full potential of these therapies.
Our capacity will directly enable:
-
Expanded Patient Access: Moving TAT from a limited, specialist treatment toward broader hospital adoption.
-
Therapeutic Growth: Supporting the development of new targeted radiopharmaceuticals and precision oncology worldwide.
-
Supply Security: Establishing sustainable production capacity and secure supply chains.
-
Quality Standards: Ensuring high-purity medical-grade isotope standards for life-saving care.
At Southern Cross Medical Radioisotopes, our multidisciplinary team of medical/nuclear physicists, biologists, radiochemists and mining experts is dedicated to driving advancements in medical science.
We are passionate about developing cutting-edge technologies and services that contribute to the betterment of Australian healthcare.
Our overriding goal is to produce the alpha-emitter production, Ac-225, for treating metastasis in cancer. We are proud to be at the forefront of pioneering solutions that address unmet medical needs.
Our commitment to excellence and innovation sets us apart in the industry, allowing us to make a significant difference in the lives of patients.